Related Experiment Video

Updated: Apr 29, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies

Eirini Katodritou1, Evangelos Terpos2

  • 1Department of Hematology Theagenio Cancer Hospital Thessaloniki Greece.

Hemasphere
|October 15, 2025
PubMed

Insights

Central nervous system multiple myeloma (CNS-MM) is a rare and aggressive cancer. This review addresses the diagnostic and therapeutic challenges of CNS-MM, offering insights for better patient management.

Area of Science:

  • Hematology
  • Neuro-oncology
  • Oncology

Background:

  • Central nervous system multiple myeloma (CNS-MM) is a rare extramedullary manifestation of multiple myeloma.
  • It is associated with a poor prognosis and presents significant treatment challenges.
  • Limited data exists on its incidence, risk factors, and optimal management.

Purpose of the Study:

  • To review the current diagnostic and therapeutic challenges of CNS-MM.
  • To provide practical insights into real-life management strategies for CNS-MM.

Main Methods:

  • Literature review of existing studies on CNS-MM.
  • Analysis of diagnostic criteria and therapeutic approaches.
  • Synthesis of real-world management data.

Main Results:

  • CNS-MM diagnosis is often delayed due to its rarity and non-specific symptoms.
  • Treatment strategies are varied and often extrapolated from systemic myeloma protocols.
  • Long-term outcomes remain poor, highlighting the need for specialized approaches.

Conclusions:

  • Improved diagnostic tools and risk stratification are crucial for CNS-MM.
  • Multidisciplinary collaboration is essential for optimizing treatment and patient care.
  • Further research is needed to establish evidence-based guidelines for CNS-MM management.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice07:14

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice

Published on: May 23, 2025

1.6K

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
24
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
19
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
49
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
51